Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 7/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25092038 | 1.00 | SIRT5 (0.44) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL21534468 | 0.96 | SIRT5 (0.48) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL17841852 | 0.94 | SIRT5 (0.49) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL19776854 | 0.94 | SIRT5 (0.49) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL19171358 | 0.90 | SIRT5 (0.40) | SIRT5SIRT6SIRT1KMT2AMEN1 | |
| SCHEMBL28574926 | 0.90 | GNPAT (0.45) | SIRT5SIRT6SIRT1FURINALB | |
| SCHEMBL18688864 | 0.90 | GNPAT (0.45) | SIRT5SIRT6SIRT1FURINALB | |
| SCHEMBL18122890 | 0.89 | SIRT5 (0.37) | SIRT5SIRT6SIRT1KMT2AFURIN | |
| SCHEMBL16091799 | 0.89 | SIRT5 (0.36) | SIRT5SIRT6SIRT1KMT2AFURIN | |
| SCHEMBL21103418 | 0.89 | SIRT5 (0.36) | SIRT5SIRT6SIRT1KMT2AFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11633501-B2 | Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210113706-A1 | MODIFIED SELF-IMMOLATING MOIETIES FOR USE IN PRODRUGS AND CONJUGATES AND METHODS OF USING AND MAKING | BRISTOL-MYERS SQUIBB COMPANY | 2021-04-22 | — | — | US | disclosed |
| WO-2021014415-A2 | SMALL MOLECULE INHIBITORS OF ACETYL COENZYME A SYNTHETASE SHORT CHAIN 2 (ACSS2) | CURADEV PHARMA PVT. LTD. (IN) | 2021-01-28 | — | — | WO | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200376136-A1 | Anti-STEAP2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind STEAP2 and CD3, and Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-10752690-B2 | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses | REGENERON PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-9950076-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9408923-B2 | Hydrophilic self-immolative linkers and conjugates thereof | BIOALLIANCE C.V. (NL) | 2016-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | PAICS, UGT1A1, CYP7A1 | SIRT5 1569/4885SIRT6 2278/4885SIRT1 1961/4885 |
| US-20200376136-A1 | Anti-STEAP2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind STEAP2 and CD3, and Uses Thereof | CD4, SPAG5, CD47 | SIRT5 4547/4885SIRT6 3597/4885SIRT1 4823/4885 |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885SIRT6 3131/4885SIRT1 1931/4885 |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | SIRT5 3045/4885SIRT6 3183/4885SIRT1 2137/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885SIRT6 3131/4885SIRT1 1931/4885 |
| US-10752690-B2 | Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses | CD22, CD2, CD47 | SIRT5 3922/4885SIRT6 3897/4885SIRT1 3906/4885 |
| US-11633501-B2 | Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof | CD4, SPAG5, CD47 | SIRT5 4547/4885SIRT6 3597/4885SIRT1 4823/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | SIRT5 3421/4885SIRT6 3492/4885SIRT1 3932/4885 |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885SIRT6 3131/4885SIRT1 1931/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885SIRT6 3131/4885SIRT1 1931/4885 |
| US-20210113706-A1 | MODIFIED SELF-IMMOLATING MOIETIES FOR USE IN PRODRUGS AND CONJUGATES AND METHODS OF USING AND MAKING | PAICS, UGT1A1, CYP7A1 | SIRT5 1569/4885SIRT6 2278/4885SIRT1 1961/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | SIRT5 2853/4885SIRT6 3364/4885SIRT1 4116/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | SIRT5 3045/4885SIRT6 3183/4885SIRT1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.